Difference between revisions of "Neuroendocrine carcinoma"
Jump to navigation
Jump to search
(Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;...") |
Warner-admin (talk | contribs) m (Text replacement - ":Section editor transclusions|" to ":Editorial board transclusions|") |
||
| Line 3: | Line 3: | ||
[[#top|Back to Top]] | [[#top|Back to Top]] | ||
</div> | </div> | ||
| − | {{#lst: | + | {{#lst:Editorial board transclusions|endo}} |
Note: these are regimens tested in histology-specific populations, please see the '''[[Neuroendocrine tumor|main NET page]]''' for other regimens. | Note: these are regimens tested in histology-specific populations, please see the '''[[Neuroendocrine tumor|main NET page]]''' for other regimens. | ||
=Advanced disease, all lines of therapy= | =Advanced disease, all lines of therapy= | ||
Revision as of 20:24, 11 August 2023
| Section editor | |
|---|---|
| Unfilled If you are interested in this role, please contact us at [email protected]. | |
Note: these are regimens tested in histology-specific populations, please see the main NET page for other regimens.
Advanced disease, all lines of therapy
Cisplatin & Etoposide (EP)
EP: Etoposide and Platinol (Cisplatin)
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Morizane et al. 2022 (TOPIC-NEC) | 2014-08-08 to 2020-03-06 | Phase 3 (E-switch-ic) | IP | Did not meet primary endpoint of OS |
Chemotherapy
- Cisplatin (Platinol) 80 mg/m2 IV once on day 1
- Etoposide (Vepesid) 100 mg/m2 IV once per day on days 1 to 3
21-day cycles
References
- TOPIC-NEC: Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. link to original article link to PMC article contains dosing details in manuscript PubMed UMIN000014795
Cisplatin & Irinotecan (IC)
IP: Irinotecan, Platinol (Cisplatin)
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Morizane et al. 2022 (TOPIC-NEC) | 2014-08-08 to 2020-03-06 | Phase 3 (E-switch-ic) | EP | Did not meet primary endpoint of OS |
Chemotherapy
- Cisplatin (Platinol) 60 mg/m2 IV once on day 1
- Irinotecan (Camptosar) 60 mg/m2 IV once per day on days 1, 8, 15
28-day cycles
References
- TOPIC-NEC: Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. link to original article link to PMC article contains dosing details in manuscript PubMed UMIN000014795